Irfan Agha, MD
Nephrology · Dallas, TXNPI 1912982489
Payments from drug & device makers
Across 1,276 payments — averaging $2312.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1.2M
- Akebia Therapeutics Inc$740K
- GSK$545K
- Vertex$143K
- Travere Therapeutics, Inc.$143K
- AstraZeneca$118K
- plus $102K from 23 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 36 | $1,160,453 |
| Akebia Therapeutics Inc | 526 | $739,565 |
| GSK | 324 | $545,469 |
| Vertex | 7 | $143,004 |
| Travere Therapeutics, Inc. | 29 | $142,919 |
| AstraZeneca(2 entities) | 136 | $118,113 |
| Calliditas Therapeutics US Inc. | 41 | $38,100 |
| Aurinia Pharma U.S., Inc. | 16 | $22,078 |
| Bayer | 14 | $16,788 |
| Biogen | 1 | $10,771 |
| Veloxis Pharmaceuticals, Inc. | 1 | $6,325 |
| Fresenius USA Marketing, Inc. | 6 | $3,664 |
| Novo Nordisk AS | 50 | $1,423 |
| Amgen(2 entities) | 38 | $1,181 |
| Vifor Pharma, Inc. | 18 | $387 |
| Otsuka America Pharmaceutical, Inc. | 4 | $191 |
| Boehringer Ingelheim | 2 | $163 |
| Novo Nordisk | 2 | $125 |
| Mallinckrodt Hospital Products Inc. | 5 | $103 |
| Mallinckrodt Enterprises LLC | 1 | $90 |
| OPKO Pharmaceuticals, LLC | 4 | $73 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $72 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $68 |
| ANI Pharmaceuticals, Inc. | 2 | $48 |
| Sanofi-aventis U.S. LLC | 1 | $46 |
| Renalytix AI, Inc. | 2 | $43 |
| Johnson & Johnson | 1 | $24 |
| Recor Medical Inc | 1 | $19 |
| Rockwell Medical, Inc. | 1 | $13 |
How this compares
$2,951,318 in reported general payments places this provider in the 95th percentile of 1,070 nephrology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in Dallas
- Ankit MehtaDallas$3M
- David WojciechowskiDallas$1.6M
- Biff PalmerDallas$867K
- Gates ColbertDallas$828K
- Mark LermanDallas$564K
- Sumit KumarDallas$561K
- Robert TotoDallas$442K
- Akinwande AkinfolarinDallas$423K
- Deepa AmberkerDallas$300K
- Pablo PergolaSan Antonio$14.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.